Skip to main content
Go to homepage

Brentuximad Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

Description:

For complete study information, please view the study on clincaltrials.gov.

Interested in participating?
We are currently recruiting
Full IRB Study Title:
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
IRB Study ID:
1038558-1
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program